Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psychiatric interview

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    225 result(s) found for: Psychiatric interview. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-005708-17 Sponsor Protocol Number: ELB139202-05 Start Date*: 2006-03-27
    Sponsor Name:elbion AG
    Full Title: International, multicenter, randomized, double-blind, placebo controlled, two-period, cross-over study to demonstrate safety, tolerability and anxiolytic effects of 600 mg ELB139 given orally t.i.d...
    Medical condition: Male and female patients with diagnosis of concurrent panic disorder according to DSM-IV, with or without agoraphobia (DSM IV 300.21 and 300.1) according to Mini International Neuropsychiatric Inte...
    Disease: Version SOC Term Classification Code Term Level
    10037175
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013028-21 Sponsor Protocol Number: ------ Start Date*: 2009-10-16
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
    Full Title: USE OF CLINICAL AND INTERMEDIATE PHENOTYPES TO ASSESS RESPONSE TO QUETIAPINE: THE ROLE OF PUTATIVE CAUSATIVE GENES
    Medical condition: schizophrenia using the Structured Clinical Interview for Diagnosis (SCID) for the Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV);
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037175 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001523-39 Sponsor Protocol Number: D1050300 Start Date*: 2013-11-08
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPE...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10001064 Acute schizophrenia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000757-13 Sponsor Protocol Number: RGH-MD-54 Start Date*: 2016-06-07
    Sponsor Name:Forest Laboratories LLC, an Allergan Affiliate
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipo...
    Medical condition: Bipolar I Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-010625-39 Sponsor Protocol Number: MZ09-PCP-SosPeter Start Date*: 2010-04-21
    Sponsor Name:Prague Psychiatric Center
    Full Title: QEEG cordance and EEG connectivity changes after administration of subanesthetic ketamine doses in depressive disorder patients
    Medical condition: INCLUSION CRITERIA: 1. Men and women at the age between 18 to 65 years, with dextromanual dominance. 2. Patients have to answer DSM IV criteria for the major depressive episode, without psychotic s...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000756-98 Sponsor Protocol Number: RGH-MD-53 Start Date*: 2016-07-19
    Sponsor Name:Forest Laboratories LLC, an Allergan Affiliate
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipo...
    Medical condition: Bipolar I Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-000089-11 Sponsor Protocol Number: AX-CL-09 Start Date*: 2004-12-15
    Sponsor Name:Axonyx Inc
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease
    Medical condition: Alzheimer's Disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimer's also affects the levels of a certain neu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004460-63 Sponsor Protocol Number: EXPO Start Date*: 2019-07-01
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): An Open Label Randomised Controlled Trial of Injectable Depot Maintenance Buprenorphine versus Standard-Of-Care Oral Maintenance Opi...
    Medical condition: Opiod addiction
    Disease: Version SOC Term Classification Code Term Level
    23.1 10037175 - Psychiatric disorders 10013658 Drug addiction LLT
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-011097-15 Sponsor Protocol Number: OLA_ZIPRA Start Date*: 2009-08-25
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Effect of atypical antipsychotics on gene expression in soft tissues of healthy subjects. A placebo controlled randomised pilot study.
    Medical condition: The study will be conducted in 42 healthy volunteers
    Disease:
    Population Age: Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002859-19 Sponsor Protocol Number: 072016 Start Date*: 2017-08-22
    Sponsor Name:Erasmus MC
    Full Title: Withdrawing off-label antipsychotics in people with intellectual disabilities: why does it fail?
    Medical condition: People with challenging behavior and off-label antipsychotic use
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003076-22 Sponsor Protocol Number: PSY-201401_ESPRIT Start Date*: 2016-07-07
    Sponsor Name:Central Institute of Mental Health Mannheim (ZI)
    Full Title: Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trial investigating the efficacy of Acetylcysteine (ACC) and Integrated Preventive Psychological Intervention (IPPI) in...
    Medical condition: Clinical High Risk state for developing a first psychotic episode
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    20.0 10037175 - Psychiatric disorders 10061920 Psychotic disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001529-24 Sponsor Protocol Number: 190-062 Start Date*: 2007-03-06
    Sponsor Name:Sepracor NV in care of Sepracor Inc.
    Full Title: Adults adminstered Venlafaxine and Eszopiclone Response to Treatment (AVERT): A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered with Venlafaxine in Subjects wit...
    Medical condition: Insomnia Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) SE (Completed) GB (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000933-12 Sponsor Protocol Number: AX-CL-10 Start Date*: 2005-02-22
    Sponsor Name:Axonyx Inc
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease
    Medical condition: Alzheimers disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimers's also affects the levels of a certain neu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004049-19 Sponsor Protocol Number: NL77938.018.23 Start Date*: 2023-10-13
    Sponsor Name:Amsterdam UMC
    Full Title: Sodium oxybate as a potential new treatment for catatonia in patients with depression, bipolar disorder or a psychotic disorder, a randomized controlled trial. The Laborit study.
    Medical condition: Catatonia in patients with depression, bipolar disorder or a psychotic disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001518-40 Sponsor Protocol Number: 848040001 Start Date*: 2020-01-31
    Sponsor Name:VU Medical Center
    Full Title: Netherlands study of Optimal, PERsonalized Antidepressant use (OPERA-DISCONTINUATION)
    Medical condition: Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002326-36 Sponsor Protocol Number: 2016-858 Start Date*: 2016-11-09
    Sponsor Name:Region Hovedstadens psykiatriske hospital
    Full Title: Effects of erythropoietin (EPO) on cognitive side-effects of electroconvulsive therapy (ECT) (EPO-T)
    Medical condition: Unipolar/bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10045543 Unipolar depression LLT
    21.1 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003789-25 Sponsor Protocol Number: mela1 Start Date*: 2015-02-26
    Sponsor Name:Department of surgery, Herlev Hospital
    Full Title: The anxiolytic effects of melatonin: A randomized, placebo-controlled, double-blinded clinical study.
    Medical condition: We intend to investigate the anxiolytic effects of melatonin in relation to surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10002855 Anxiety PT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000952-17 Sponsor Protocol Number: NT13403 Start Date*: 2013-04-29
    Sponsor Name:Prague Psychiatric Centre
    Full Title: The Role of mTOR (Mammalian Target of Rapamycin) Signaling Pathway in the Antidepressive Effect of Ketamine in Patients with Depressive Disorder.
    Medical condition: 1. Men and women at the age between 18 to 65 years, with dextromanual dominance. 2. Patients have to answer DSM IV criteria for the major depressive episode, without psychotic symptoms, on the clin...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004054-28 Sponsor Protocol Number: Panorexia Start Date*: 2020-06-23
    Sponsor Name:Imperial College London
    Full Title: Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study
    Medical condition: Anorexia Nervosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10002646 Anorexia LLT
    20.0 10037175 - Psychiatric disorders 10002649 Anorexia nervosa PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-006108-34 Sponsor Protocol Number: 10140021910006 Start Date*: 2022-09-29
    Sponsor Name:AmsterdamUMC (location VUmc)
    Full Title: Trial Examining Methods for Antidepressant Discontinuation
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10025464 Major depressive disorder, single episode in full remission LLT
    21.1 10037175 - Psychiatric disorders 10025455 Major depressive disorder, recurrent episode, in full remission LLT
    20.0 10037175 - Psychiatric disorders 10025465 Major depressive disorder, single episode, in partial or unspecified remission LLT
    20.0 10037175 - Psychiatric disorders 10025456 Major depressive disorder, recurrent episode, in partial or unspecified remission LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA